{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T02:12:32Z","timestamp":1781835152484,"version":"3.54.5"},"reference-count":23,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2019,10,9]],"date-time":"2019-10-09T00:00:00Z","timestamp":1570579200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008273","name":"novartis foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008273","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Ophthalmology"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To evaluate the additive intraocular pressure\u2013lowering effect of twice-daily brinzolamide 1%\/brimonidine 0.2% fixed-dose combination (BBFC) as an adjunct to a prostaglandin analog (PGA) in patients with open-angle glaucoma or ocular hypertension insufficiently controlled with PGA monotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>In this Phase 4, double-masked trial, patients aged \u2a7e18 years, with a mean intraocular pressure of \u2a7e19 and &lt;32 mm Hg in at least one eye were randomized (1:1) to receive BBFC + PGA ( n = 96) or vehicle + PGA ( n = 92) for 6 weeks. The primary endpoint was the mean change in diurnal intraocular pressure from baseline (averaged over 09:00 and 11:00 h) at Week 6.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The mean diurnal intraocular pressure at baseline was similar in the BBFC + PGA (22.8 mm Hg) and vehicle + PGA (22.9 mm Hg) groups. The least squares mean change in diurnal intraocular pressure from baseline at Week 6 was greater with BBFC + PGA (\u22125.59 mm Hg (95% confidence interval: \u22126.2 to \u22125.0)) than with vehicle + PGA (\u22122.15 mm Hg (95% confidence interval: \u22122.7 to \u22121.6)); the treatment difference was statistically significant in favor of BBFC + PGA (\u22123.44 mm Hg, (95% confidence interval: \u22124.2 to \u22122.7); p &lt; 0.001). Ocular adverse events were reported in 21.1% and 8.7% of patients in the BBFC + PGA and vehicle + PGA groups, respectively. The most frequent ocular adverse event was ocular hyperemia (5.3%) in the BBFC + PGA group and blurred vision (2.2%) in the vehicle + PGA group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>BBFC + PGA significantly reduced mean diurnal intraocular pressure than PGA alone in patients with open-angle glaucoma or ocular hypertension. The safety findings with BBFC + PGA were consistent with the known safety profile of the individual medications.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1120672119878044","type":"journal-article","created":{"date-parts":[[2019,10,9]],"date-time":"2019-10-09T06:29:31Z","timestamp":1570602571000},"page":"103-111","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":9,"title":["Brinzolamide\/brimonidine fixed-dose combination bid as an adjunct to a prostaglandin analog for open-angle glaucoma\/ocular hypertension"],"prefix":"10.1177","volume":"31","author":[{"given":"Fotis","family":"Topouzis","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, School of Medicine, Aristotle University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Goldberg","sequence":"additional","affiliation":[{"name":"Discipline of Ophthalmology, The University of Sydney, Sydney, NSW, Australia"},{"name":"Glaucoma Unit, Sydney Eye Hospital, Sydney, NSW, Australia"},{"name":"Eye Associates, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Bell","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J","family":"Tatham","sequence":"additional","affiliation":[{"name":"Princess Alexandra Eye Pavilion and Department of Ophthalmology, University of Edinburgh, Edinburgh, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Ridolfi","sequence":"additional","affiliation":[{"name":"Novartis Pharma S.A.S, Rueil-Malmaison, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Hubatsch","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceutical Corporation, Fort Worth, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo","family":"Nicolela","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology & Visual Sciences, Dalhousie University, Halifax, NS, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillipe","family":"Denis","sequence":"additional","affiliation":[{"name":"Service d\u2019Ophtalmologie, H\u00f4pital de la Croix-Rousse, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S Fabian","family":"Lerner","sequence":"additional","affiliation":[{"name":"Consultorio Oftalmologico Dr. Fabian Lerner and Facultad de Ciencias Medicas, Universidad Favaloro, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2019,10,9]]},"reference":[{"key":"bibr1-1120672119878044","doi-asserted-by":"publisher","DOI":"10.1177\/112067210801800517"},{"key":"bibr2-1120672119878044","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(02)01585-4"},{"key":"bibr3-1120672119878044","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2008.08.006"},{"key":"bibr4-1120672119878044","doi-asserted-by":"publisher","DOI":"10.1111\/aos.12203"},{"key":"bibr5-1120672119878044","doi-asserted-by":"crossref","unstructured":"European Glaucoma Society. Terminology and guidelines for glaucoma. 4th ed., https:\/\/www.eugs.org\/eng\/egs_guidelines_reg.asp?l=1 (accessed 11 August 2018).","DOI":"10.1136\/bjophthalmol-2016-EGSguideline.001"},{"key":"bibr6-1120672119878044","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2007.10.004"},{"key":"bibr7-1120672119878044","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.120.6.701"},{"key":"bibr8-1120672119878044","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(01)00873-9"},{"key":"bibr9-1120672119878044","doi-asserted-by":"publisher","DOI":"10.1023\/A:1002453604171"},{"key":"bibr10-1120672119878044","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2004.12.026"},{"key":"bibr11-1120672119878044","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2007.06.012"},{"key":"bibr12-1120672119878044","doi-asserted-by":"publisher","DOI":"10.1185\/03007990903260129"},{"key":"bibr13-1120672119878044","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2006.08.033"},{"key":"bibr14-1120672119878044","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2016.126"},{"key":"bibr15-1120672119878044","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2016.02.026"},{"key":"bibr16-1120672119878044","doi-asserted-by":"publisher","DOI":"10.1007\/s10865-007-9147-y"},{"key":"bibr17-1120672119878044","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.120.10.1268"},{"key":"bibr18-1120672119878044","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1995.01100070092031"},{"key":"bibr19-1120672119878044","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2007.03.017"},{"key":"bibr20-1120672119878044","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2007.03.016"},{"issue":"14","key":"bibr21-1120672119878044","first-page":"2019","volume":"117","author":"Nygaard HA","year":"1997","journal-title":"Tidsskr Nor Laegeforen"},{"key":"bibr22-1120672119878044","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S44708"},{"key":"bibr23-1120672119878044","doi-asserted-by":"publisher","DOI":"10.1097\/00061198-199300230-00003"}],"container-title":["European Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1120672119878044","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1120672119878044","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1120672119878044","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T19:44:55Z","timestamp":1777405495000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1120672119878044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,9]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["10.1177\/1120672119878044"],"URL":"https:\/\/doi.org\/10.1177\/1120672119878044","relation":{},"ISSN":["1120-6721","1724-6016"],"issn-type":[{"value":"1120-6721","type":"print"},{"value":"1724-6016","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,9]]}}}